← FDA DRUG APPROVALS

FDA ANDA · ANDA206685

ESTRADIOL

Sponsor: MYLAN TECHNOLOGIES

APPLICATION
ANDA206685
TYPE
ANDA
ORIGINAL APPROVAL
2018-08-15
LATEST ACTION
2024-12-06
ROUTE
TRANSDERMAL
DOSAGE FORM
FILM, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

ESTRADIOLPrescription
ESTRADIOL 0.1MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
ESTRADIOLPrescription
ESTRADIOL 0.05MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
ESTRADIOLPrescription
ESTRADIOL 0.025MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
ESTRADIOLPrescription
ESTRADIOL 0.075MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
ESTRADIOLPrescription
ESTRADIOL 0.0375MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL

Approval history

2024-12-06Labeling · Supplement 7 · standardAP
2024-12-06Labeling · Supplement 4 · standardAP
2018-08-15UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →